Skip to content

Sample Page

Author: XORTX Therapeutics Inc.

Posted Date:

June 15, 2026

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

XORTX Therapeutics Inc.

June 15, 2026
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Therapeutics Inc.

June 12, 2026
XORTX Announces Closing of US$5 Million Public Offering

XORTX Therapeutics Inc.

May 19, 2026
XORTX Announces US$5 Million Public Offering

XORTX Therapeutics Inc.

May 14, 2026
XORTX Meets Nasdaq Continued Listing Requirements

XORTX Therapeutics Inc.

April 21, 2026
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

XORTX Therapeutics Inc.

April 14, 2026
XORTX Confirms Effective Date of Share Consolidation

XORTX Therapeutics Inc.

April 2, 2026
XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Therapeutics Inc.

March 27, 2026
XORTX Announces Share Consolidation

XORTX Therapeutics Inc.

March 25, 2026
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

XORTX Therapeutics Inc.

March 24, 2026

1 2